{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:14:01Z","timestamp":1792782841112,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000300","name":"National Osteoporosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000300","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute for Health Research Clinician Scientist award","award":["CS-2013-13-012"],"award-info":[{"award-number":["CS-2013-13-012"]}],"id":[{"id":"https:\/\/ror.org\/0187kwz08","id-type":"ROR","asserted-by":"crossref"}]},{"name":"NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol","id":[{"id":"https:\/\/ror.org\/0524sp257","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00198-021-06262-1","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T04:42:41Z","timestamp":1644381761000},"page":"1579-1589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database"],"prefix":"10.1007","volume":"33","author":[{"given":"S.","family":"Khalid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Calderon-Larranaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Judge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Arden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. P.","family":"Van Staa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Abrahamsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Kassim","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Prieto-Alhambra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"6262_CR1","doi-asserted-by":"publisher","unstructured":"Sambrook P, Cooper C (2006) Osteoporosis. Lancet (London, England) 367(9527):2010\u20132018. https:\/\/doi.org\/10.1016\/S0140-6736(06)68891-0","DOI":"10.1016\/S0140-6736(06)68891-0"},{"key":"6262_CR2","unstructured":"National Institute for Health and Care Excellence (NICE) (2008) Alendronate, etidronate, risedronate, raloxifene and strontium\u00a0ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. http:\/\/www.laalamedilla.org\/GUIAS\/Guia%20NICE%20osteoporosis%20P12011.pdf"},{"key":"6262_CR3","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1007\/s00198-012-1894-0","volume":"23","author":"J-HJ-H Kang","year":"2012","unstructured":"Kang J-HJ-H, Keller JJ, Lin H-CH-C (2012) A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke. Osteoporos Int 23:2551\u20132557. https:\/\/doi.org\/10.1007\/s00198-012-1894-0","journal-title":"Osteoporos Int"},{"key":"6262_CR4","first-page":"168","volume":"66","author":"B Huang","year":"2015","unstructured":"Huang B, Huang F, Gui Y et al (2015) Association between bisphosphonates therapy and incident myocardial infarction: meta-analysis and trial sequential analysis. J Cardiovasc Pharmacol 66:168\u2013477","journal-title":"J Cardiovasc Pharmacol"},{"key":"6262_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122646","volume":"10","author":"DH Kim","year":"2015","unstructured":"Kim DH, Rogers JR, Fulchino LA et al (2015) Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS ONE 10:e0122646. https:\/\/doi.org\/10.1371\/journal.pone.0122646","journal-title":"PLoS ONE"},{"key":"6262_CR6","unstructured":"European Medicines Agency (2013) Protelos-H-C-560-PSU-31: EPAR. Assessment report. Periodic safety update report. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000560\/WC500147168.pdf"},{"key":"6262_CR7","doi-asserted-by":"publisher","unstructured":"Bolland MJ, Grey A (2016) Ten years too long: strontium ranelate, cardiac events, and the European Medicines Agency.\u00a0BMJ (Clinical research ed.) 354:i5109.\u00a0https:\/\/doi.org\/10.1136\/bmj.i5109","DOI":"10.1136\/bmj.i5109"},{"key":"6262_CR8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00198-013-2582-4","volume":"25","author":"C Cooper","year":"2014","unstructured":"Cooper C, Fox KM, Borer JS (2014) Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD. Osteoporos Int 25:737\u2013745","journal-title":"Osteoporos Int"},{"key":"6262_CR9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00198-013-2469-4","volume":"25","author":"B Abrahamsen","year":"2014","unstructured":"Abrahamsen B, Grove EL, Vestergaard P (2014) Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporos Int 25:757\u2013762","journal-title":"Osteoporos Int"},{"key":"6262_CR10","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1136\/annrheumdis-2014-205283","volume":"73","author":"H Svanstr\u00f6m","year":"2014","unstructured":"Svanstr\u00f6m H, Pasternak B, Hviid A (2014) Use of strontium ranelate and risk of acute coronary syndrome: cohort study. Ann Rheum Dis 73:1037\u20131043","journal-title":"Ann Rheum Dis"},{"key":"6262_CR11","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s00296-012-2594-y","volume":"33","author":"M Audran","year":"2013","unstructured":"Audran M, Jakob FJ, Palacios S et al (2013) A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years. Rheumatol Int 33:2231\u20132239","journal-title":"Rheumatol Int"},{"key":"6262_CR12","doi-asserted-by":"publisher","unstructured":"\u25bd Strontium ranelate discontinued (2017) Drug and therapeutics bulletin. Advance online\u00a0publication. https:\/\/doi.org\/10.1136\/dtb.2017.8.0507","DOI":"10.1136\/dtb.2017.8.0507"},{"key":"6262_CR13","first-page":"125","volume":"355","author":"E Barrett-Connor","year":"2002","unstructured":"Barrett-Connor E, Mosca L, Collins P et al (2002) Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. JAMA 355:125\u2013137","journal-title":"JAMA"},{"key":"6262_CR14","doi-asserted-by":"publisher","unstructured":"Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD, MORE Investigators (Multiple Outcomes of Raloxifene Evaluation) (2002) Raloxifene and cardiovascular events in osteoporotic\u00a0postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.\u00a0JAMA 287(7):847\u2013857. https:\/\/doi.org\/10.1001\/jama.287.7.847","DOI":"10.1001\/jama.287.7.847"},{"key":"6262_CR15","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799\u20131809","journal-title":"N Engl J Med"},{"key":"6262_CR16","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1210\/jc.2004-1774","volume":"90","author":"J-Y Reginster","year":"2005","unstructured":"Reginster J-Y, Wilson KM, Dumont E et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816\u20132822","journal-title":"J Clin Endocrinol Metab"},{"key":"6262_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.recesp.2011.07.017","volume":"65","author":"R Ramos","year":"2012","unstructured":"Ramos R, Ballo E, Marrugat J et al (2012) Validity for use in research on vascular diseases of the SIDIAP (Information System for the Development of Research in Primary Care): the EMMA study. Rev Esp Cardiol (Engl Ed) 65:29\u201337. https:\/\/doi.org\/10.1016\/j.recesp.2011.07.017","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"6262_CR18","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","volume":"44","author":"E Herrett","year":"2015","unstructured":"Herrett E, Gallagher AM, Bhaskaran K et al (2015) Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol 44:827\u2013836. https:\/\/doi.org\/10.1093\/ije\/dyv098","journal-title":"Int J Epidemiol"},{"key":"6262_CR19","doi-asserted-by":"publisher","unstructured":"Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. (1993). Am J Med 94(6):646\u2013650. https:\/\/doi.org\/10.1016\/0002-9343(93)90218-e","DOI":"10.1016\/0002-9343(93)90218-e"},{"key":"6262_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jclinepi.2007.07.011","volume":"61","author":"PC Austin","year":"2008","unstructured":"Austin PC (2008) The performance of different propensity-score methods for estimating relative risks. J Clin Epidemiol 61:537\u2013545. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.07.011","journal-title":"J Clin Epidemiol"},{"key":"6262_CR21","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496\u2013509. https:\/\/doi.org\/10.1080\/01621459.1999.10474144","journal-title":"J Am Stat Assoc"},{"key":"6262_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","volume":"40","author":"L Scrucca","year":"2007","unstructured":"Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transpl 40:381\u2013387","journal-title":"Bone Marrow Transpl"},{"key":"6262_CR23","volume-title":"European cardiovascular disease statistics 2012","author":"M Nichols","year":"2012","unstructured":"Nichols M, Townsend N, Scarborough P, Rayner M (2012) European cardiovascular disease statistics 2012. European Heart Network, Brussels"},{"key":"6262_CR24","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s10654-018-0427-3","volume":"33","author":"C Galbete","year":"2018","unstructured":"Galbete C, Schwingshackl L, Schwedhelm C et al (2018) Evaluating Mediterranean diet and risk of chronic disease in cohort studies: an umbrella review of meta-analyses. Eur J Epidemiol 33:909\u2013931. https:\/\/doi.org\/10.1007\/s10654-018-0427-3","journal-title":"Eur J Epidemiol"},{"key":"6262_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.mayocp.2013.08.021","volume":"89","author":"CB Pittman","year":"2014","unstructured":"Pittman CB, Davis LA, Zeringue AL et al (2014) Myocardial infarction risk among patients with fractures receiving bisphosphonates. Mayo Clin Proc 89:43\u201351","journal-title":"Mayo Clin Proc"},{"key":"6262_CR26","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/jbmr.3448","volume":"33","author":"C-W Sing","year":"2018","unstructured":"Sing C-W, Wong AYS, Kiel DP et al (2018) Association of alendronate and risk of cardiovascular events in patients with hip fracture. J Bone Miner Res 33:1422\u20131434. https:\/\/doi.org\/10.1002\/jbmr.3448","journal-title":"J Bone Miner Res"},{"key":"6262_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ijcard.2014.07.008","volume":"176","author":"A Synetos","year":"2014","unstructured":"Synetos A, Toutouzas K, Benetos G et al (2014) No catheter based inhibition of arterial calcification by bisphosphonates in an experimental atherosclerotic rabbit animal model. Int J Cardiol 176:177\u2013181","journal-title":"Int J Cardiol"},{"key":"6262_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00223-011-9549-2","volume":"90","author":"P Vestergaard","year":"2012","unstructured":"Vestergaard P (2012) Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and no. Calcif Tissue Int 90:22\u201329","journal-title":"Calcif Tissue Int"},{"key":"6262_CR29","unstructured":"European Medicines Agency (2013) EMA\/258269\/2013. Recommendation to restrict the use of Protelos\/Osseor (strontium\u00a0ranelate) CHMP confirms recommendation from the PRAC. https:\/\/www.ema.europa.eu\/en\/documents\/pressrelease\/recommendation-restrict-use-protelos\/osseor-strontium-ranelate_en.pdf"},{"key":"6262_CR30","doi-asserted-by":"publisher","unstructured":"Bolland MJ, Grey A (2014) A comparison of adverse event and fracture efficacy data for strontium ranelate in\u00a0regulatory documents and the publication record. BMJ open 4(10):e005787. https:\/\/doi.org\/10.1136\/bmjopen-2014-005787","DOI":"10.1136\/bmjopen-2014-005787"},{"key":"6262_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s12020-015-0721-8","volume":"53","author":"M Atteritano","year":"2016","unstructured":"Atteritano M, Catalano A, Santoro D et al (2016) Effects of strontium ranelate on markers of cardiovascular risk in postmenopausal osteoporotic women. Endocrine 53:305\u2013312. https:\/\/doi.org\/10.1007\/s12020-015-0721-8","journal-title":"Endocrine"},{"key":"6262_CR32","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.amjcard.2005.09.083","volume":"97","author":"K Ensrud","year":"2006","unstructured":"Ensrud K, Genazzani AR, Geiger MJ et al (2006) Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol 97:520\u2013527","journal-title":"Am J Cardiol"},{"key":"6262_CR33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125\u2013137. https:\/\/doi.org\/10.1056\/NEJMoa062462","journal-title":"N Engl J Med"},{"key":"6262_CR34","doi-asserted-by":"publisher","unstructured":"Lu PY, Hsieh CF, Tsai YW, Huang WF (Sep 2011) Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. Clin Ther 33(9):1173\u20131179. https:\/\/doi.org\/10.1016\/j.clinthera.2011.07.012","DOI":"10.1016\/j.clinthera.2011.07.012"},{"key":"6262_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3399\/bjgp10X483562","volume":"60","author":"NF Khan","year":"2010","unstructured":"Khan NF, Harrison SE, Rose PW (2010) Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 60:128\u2013136","journal-title":"Br J Gen Pract"},{"key":"6262_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1365-2125.2009.03537.x","volume":"69","author":"E Herrett","year":"2010","unstructured":"Herrett E, Thomas SL, Schoonen WM et al (2010) Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Cinical Pharmacol 69:4\u201314","journal-title":"Br J Cinical Pharmacol"},{"key":"6262_CR37","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1161\/01.CIR.101.22.2572","volume":"101","author":"C Varas-Lorenzo","year":"2000","unstructured":"Varas-Lorenzo C, Garc\u00eda-Rodr\u00edguez LA, Perez-Gutthann S, Duque-Oliart A (2000) Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. Circulation 101:2572\u20132578","journal-title":"Circulation"},{"key":"6262_CR38","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/pds.1672","volume":"17","author":"TA Hammad","year":"2008","unstructured":"Hammad TA, McAdams MA, Feight A et al (2008) Determining the predictive value of Read\/OXMIS codes to identify incident acute myocardial infarction in the General Practice Research Database. Pharmacoepidemiol Drug Saf 17:1197\u20131201","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6262_CR39","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1136\/bmj.330.7498.1021","volume":"330","author":"S-LT Normand","year":"2005","unstructured":"Normand S-LT, Sykora K, Li P et al (2005) Readers guide to critical appraisal of cohort studies: 3 Analytical strategies to reduce confounding. BMJ 330:1021\u20131023","journal-title":"BMJ"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-06262-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-021-06262-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-06262-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T08:09:03Z","timestamp":1654848543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-021-06262-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["6262"],"URL":"https:\/\/doi.org\/10.1007\/s00198-021-06262-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Independent Scientific Advisory Committee (ISAC, protocol number 14_110). Ethics approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The corresponding author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to (i) publish, reproduce, distribute, display, and store the contribution; (ii) translate the contribution into other languages, create adaptations and reprints, and include within collections and create summaries, extracts, and\/or abstracts of the contribution; (iii) create any other derivative work(s) based on the contribution; (iv) exploit all subsidiary rights in the contribution; (v) the inclusion of electronic links from the contribution to third party material wherever it may be located; and (vi) licence any third party to do any or all of the above.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The lead author affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned have been explained.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency statement"}},{"value":"The study funder had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. All authors had full access to all of the data in the study and take responsibility for the integrity of such data and the accuracy of the data analysis.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"All authors have completed the ICMJE uniform disclosure form at\n                      \n                      and declare Cyrus Cooper reports Personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda, and UCB. Kassim Javaid reports honoraria, unrestricted research grants, and travel and\/or subsistence expenses from Amgen, Lilly UK, Shire, Internis, Consilient Health, Stirling Anglia Pharmaceuticals, Mereo Biopharma, Optasia Medical, Zebra Medical Vision, Kyowa Kirin Hakin, and UCB. Andrew Judge reports consultancy fees, lecture fees, and honoraria from Servier, UK Renal Registry, Oxford Craniofacial Unit, IDIAP Jordi Gol, and Freshfields Bruckhaus Deringer, is a member of the Data Safety and Monitoring Board (which involved receipt of fees) from Anthera Pharmaceuticals, Inc., and received consortium research grants from Roche. Bo Abrahamsen reports Institutional research grants UCB and Novartis. Advisory board and consulting fees UCB. Daniel Prieto Alhambra reports DPA\u2019s institution received speaker fees from AMGEN and UCB Biopharma; consultancy fees from UCB Biopharma; research grants from UCB, Amgen, and Les Laboratoires Servier; and financial support to organise educational activities from Janssen (on behalf of IMI-funded EHDEN and EMIF consortiums) and Synapse Management Partners. Sara Khalid, Sara Calderon-Larranaga, Arvind Sami, Samuel Hawley, and Tjeerd P Van Staa declare that they have no conflict of interest.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}